Results 121 to 130 of about 21,298 (206)

Chidamide combined with fulvestrant in the treatment of HR-positive, HER2-negative advanced breast cancer after failure of previous endocrine therapy: a single-arm, single-center, phase 2 study. [PDF]

Breast Cancer Res
Zou, Tang X, Deng P, Liu Y, Yang T, Tan X, Yang L, Li W, Zeng X.   +8 more
europepmc   +1 more source

Efficacy and Mechanisms of CDK4/6 Inhibitors in Breast Cancer: Advancing Targeted Therapeutic Strategies. [PDF]

Oncol Res
Patwekar M, Patwekar F, Kari ZA, Zain MRAM, Mohammed A, Sharma R.   +5 more
europepmc   +1 more source

Mutant p53 binds and controls estrogen receptor activity to drive endocrine resistance in ovarian cancer. [PDF]

Genes Dev
Shao C, Indeglia A, Foster M, Casey K, Leung J, Modarai SR, Leu JI, Duong B, Mes-Masson AM, Sims-Mourtada J, Auslander N, Drapkin R, Bitler BG, Zhang N, Murphy ME.   +14 more
europepmc   +1 more source

Optimizing second-line endocrine-based treatment in HR positive HER2 negative metastatic breast cancer: a comprehensive expert statement from the Gulf Cooperation Council Region. [PDF]

Front Oncol
Alshehri A, Altwairgi AK, AlTourah A, Alwbari A, Chehal A, Calaud F, Al-Hashem H, Marashi H, Elsamany S, Tirmazy SH.   +9 more
europepmc   +1 more source

Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HR+/HER2- Metastatic Breast Cancer 2025. [PDF]

Curr Oncol
Jerzak KJ, Kumar A, Boileau JF, Bouganim N, Brezden-Masley C, Cao JQ, Cescon DW, Chia S, Edwards S, Joy AA, Laing K, LeVasseur N, Lupichuk S, Sehdev S, Simmons C, Webster M, Gelmon KA, Manna M, On Behalf Of Patient Advocacy Breast Cancer Canada.   +18 more
europepmc   +1 more source

Targeted therapies for ER+/HER2- metastatic breast cancer [PDF]

, 2015

core   +1 more source

Afuresertib plus fulvestrant for pretreated HR-positive, HER2-negative, advanced breast cancer: a phase Ib trial. [PDF]

Nat Commun
Zhang P, Sun T, Wang Y, Li W, Tong Z, Phadke S, Feinstein T, Ma W, Guo P, Zhang M, Yue Y, Xu B.   +11 more
europepmc   +1 more source

Exploration of real-world outcomes in patients with previously treated HR+/HER2- and triple negative metastatic breast cancer. [PDF]

Sci Rep
Sadetsky N, Prince P, Latimer H, Advani P, Smith-Gaziani D, Kaufman PA, Natanzon Y, Taylor A, Nguyen L, Freemantle N.   +9 more
europepmc   +1 more source

CDK4/6 inhibitor rechallenge therapy in advanced breast cancer. [PDF]

Discov Oncol
Sun Y, Zhao Y, Yu X, Qi Y, Dai X.
europepmc   +1 more source

DESTINY-Breast08: A Phase Ib Study of Trastuzumab Deruxtecan in Combination with Other Anticancer Therapies in Patients with HER2-Low Metastatic Breast Cancer. [PDF]

Clin Cancer Res
Jhaveri K, Loi S, Hamilton E, Schmid P, Anders CK, Testa L, Wildiers H, Tseng LM, Lu YS, Park YH, Im SA, Chen SC, Young RR, Lloyd C, Wrona M, Zhang C, Carroll D, André F.   +17 more
europepmc   +1 more source